2-(3-乙酰基苯胺基)苯甲酸 | 27696-28-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(3-乙酰基苯胺基)苯甲酸
• 英文名称: N-(3-acetylphenyl)anthranilic acid
• 英文别名: N-(3-acetyl-phenyl)-anthranilic acid；N-(3-Acetyl-phenyl)-anthranilsaeure；Anthranilic acid, N-(m-acetylphenyl)-；2-(3-acetylanilino)benzoic acid
• CAS: 27696-28-2
• 化学式: C₁₅H₁₃NO₃
• 分子量: 255.273
• InChiKey: URNBQFPUGNNQRC-UHFFFAOYSA-N

物化性质

• 熔点：
  166 °C
• 沸点：
  447.3±30.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3-乙酰基苯胺基)苯甲酸 生成 1-(3-苯基氨基苯基)-乙酮
  参考文献：
  名称：

  CCCXXVI.-10-Chloro-5：10-二氢吩那嗪及其衍生物。第十五部分。单酰基衍生物

  摘要：

  DOI：

  10.1039/jr9310002381
• 作为产物：
  描述：

  N-(3-acetylphenyl)anthranilic acid methyl ester 在 potassium hydroxide 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 以83%的产率得到2-(3-乙酰基苯胺基)苯甲酸
  参考文献：
  名称：

  Development of Potent and Selective Inhibitors of Aldo–Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on N-Phenyl-Aminobenzoates and Their Structure–Activity Relationships

  摘要：

  Aldo-keto reductase 1C3 (AKR1C3; type 5 17 beta-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated in the intratumoral biosynthesis of testosterone and 5 alpha-dihydrotestosterone. Selective AKR1C3 inhibitors are required because compounds should not inhibit the highly related AKR1C1 and AKR1C2 isoforms which are involved in the inactivation of Sa-dihydrotestosterone. NSAIDs, N-phenylanthranilates in particular, are potent but nonselective AKR1C3 inhibitors. Using flufenamic acid, 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid, as lead compound, five classes of structural analogues were synthesized and evaluated for AKR1C3 inhibitory potency and selectivity. Structure-activity relationship (SAR) studies revealed that a meta-carboxylic acid group relative to the amine conferred pronounced AKR1C3 selectivity without loss of potency, while electron withdrawing groups on the phenylamino B-ring were optimal for AKR1C3 inhibition. Lead compounds did not inhibit COX-1 or COX-2 but blocked the AKR1C3 mediated production of testosterone in LNCaP-AKR1C3 cells. These compounds offer promising leads toward new therapeutics for CRPC.

  DOI：

  10.1021/jm201547v

文献信息

• Kaltenbronn; Scherrer; Short, Arzneimittel-Forschung/Drug Research, 1983, vol. 33, # 4 A, p. 621 - 627
  作者：Kaltenbronn、Scherrer、Short、Jones、Beatty、Saka、Winder、Wax、Williamson

  DOI：——

  日期：——
• CCCXXVI.—10-Chloro-5 : 10-dihydrophenarsazine and its derivatives. Part XV. Monoacyl derivatives
  作者：Leslie Alderman Elson、Charles Stanley Gibson

  DOI：10.1039/jr9310002381

  日期：——
• Development of Potent and Selective Inhibitors of Aldo–Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on <i>N</i>-Phenyl-Aminobenzoates and Their Structure–Activity Relationships
  作者：Adegoke O. Adeniji、Barry M. Twenter、Michael C. Byrns、Yi Jin、Mo Chen、Jeffrey D. Winkler、Trevor M. Penning

  DOI：10.1021/jm201547v

  日期：2012.3.8

  Aldo-keto reductase 1C3 (AKR1C3; type 5 17 beta-hydroxysteroid dehydrogenase) is overexpressed in castration resistant prostate cancer (CRPC) and is implicated in the intratumoral biosynthesis of testosterone and 5 alpha-dihydrotestosterone. Selective AKR1C3 inhibitors are required because compounds should not inhibit the highly related AKR1C1 and AKR1C2 isoforms which are involved in the inactivation of Sa-dihydrotestosterone. NSAIDs, N-phenylanthranilates in particular, are potent but nonselective AKR1C3 inhibitors. Using flufenamic acid, 2-[3-(trifluoromethyl)phenyl]amino}benzoic acid, as lead compound, five classes of structural analogues were synthesized and evaluated for AKR1C3 inhibitory potency and selectivity. Structure-activity relationship (SAR) studies revealed that a meta-carboxylic acid group relative to the amine conferred pronounced AKR1C3 selectivity without loss of potency, while electron withdrawing groups on the phenylamino B-ring were optimal for AKR1C3 inhibition. Lead compounds did not inhibit COX-1 or COX-2 but blocked the AKR1C3 mediated production of testosterone in LNCaP-AKR1C3 cells. These compounds offer promising leads toward new therapeutics for CRPC.
• Itier,J.; Casadevall,A., Bulletin de la Societe Chimique de France, 1969, p. 2342 - 2355
  作者：Itier,J.、Casadevall,A.

  DOI：——

  日期：——